Director Stephen L. Sabba of Ligand Pharmaceuticals (NASDAQ:LGND) completed an open-market sale of 2,034 shares of the company’s common stock on March 3, 2026, at $201.50 per share, yielding $409,851 in gross proceeds. On the same day, Sabba exercised stock options to acquire an additional 2,034 shares at an exercise price of $69.51 per share, for a total exercise cost of $141,383.
After these transactions, Sabba directly holds 33,793 shares of Ligand Pharmaceuticals common stock.
These moves took place while LGND was trading close to its 52-week high of $212.49 and after the shares delivered an 81% return over the prior 12 months.
Separately, InvestingPro’s analysis included in company coverage indicates that the shares currently appear overvalued relative to InvestingPro’s calculated Fair Value. Investors are directed to InvestingPro for 13 additional ProTips and a fuller set of financial metrics available on its research platform.
Earnings and full-year results
Ligand reported a stronger-than-expected fourth quarter, posting earnings per share of $2.02 versus the analyst consensus of $1.49. Quarterly revenue was $59.7 million, above the consensus estimate of $55.6 million.
For the full year, Ligand recorded total revenue of $268 million and core revenue of $240 million. The company reported a full-year adjusted earnings per share figure of $8.13.
Analyst notes
In response to the company’s reported results and outlook, Oppenheimer increased its price target for Ligand Pharmaceuticals to $277 while maintaining an Outperform rating, citing a favorable royalty outlook. Stifel reiterated a Buy rating and kept its price target at $230.
Ligand also indicated that updates on its royalty asset base are expected to be provided throughout 2026.
Bottom line
The director-level sale and simultaneous option exercise are concrete, recorded transactions that leave Sabba with 33,793 directly held shares. The company's recent quarterly performance exceeded analyst expectations and prompted continued analyst support with raised and reiterated price targets, while InvestingPro’s valuation view flags the stock as appearing overvalued relative to its Fair Value.
Key points
- S. L. Sabba sold 2,034 shares on March 3, 2026, at $201.50, totaling $409,851, and exercised options for 2,034 shares at $69.51, costing $141,383.
- Ligand’s Q4 EPS of $2.02 and revenue of $59.7 million both exceeded analyst expectations; full-year revenue was $268 million and adjusted EPS was $8.13.
- Analysts Oppenheimer and Stifel maintained constructive stances, with Oppenheimer raising its target to $277 and Stifel holding a $230 target; royalty asset updates are expected during 2026.
Risks and uncertainties
- InvestingPro’s valuation assessment indicates the stock appears overvalued relative to its Fair Value, which may affect investor perception of downside risk in the equity - impacting equity markets and healthcare sector allocations.
- Future updates on Ligand’s royalty asset base are scheduled throughout 2026; the timing and content of those updates could influence expectations for licensing and royalty-driven revenue streams in the biotech and pharmaceutical sectors.
- Analyst targets and ratings can change; while two firms currently express positive views, any revision could alter investor sentiment toward LGND and related healthcare stocks.